Case Scenario C — TechPulse Data-Privacy DilemmaTechPulse In…
Case Scenario C — TechPulse Data-Privacy DilemmaTechPulse Inc. is a mid-sized software company that recently discovered its flagship analytics platform inadvertently collects sensitive personal health information from users who did not consent to that collection. Legal counsel confirms the practice is prohibited in some states but not others, with federal legislation pending. The marketing team views the data as commercially valuable and proposes selling it to pharmaceutical partners for targeted advertising. The CEO is under investor pressure to raise quarterly revenue. Several employees have raised ethical concerns internally and been told to ‘focus on the bottom line,’ and a whistleblower has signaled she may contact regulators if the company proceeds.If TechPulse sells user health data to pharmaceutical partners without informed consent, which stakeholder group faces the most direct and immediate harm?
Read DetailsCase Scenario E — Delta Components Capital BudgetingDelta Co…
Case Scenario E — Delta Components Capital BudgetingDelta Components is evaluating new projects using its 10% required rate of return. One project, ‘Line Upgrade,’ requires an initial outlay of $150,000 and is expected to generate after-tax cash flows of $60,000 per year for three years. (The present-value annuity factor for 3 years at 10% is 2.487.) The firm is separately comparing Project X (NPV = +$85,000) and Project Y (NPV = −$12,000), both evaluated at the 12% cost of capital. Delta’s finance team also analyzes a stock with a beta of 1.8; the risk-free rate is 4% and the expected market return is 10%.Delta compares Project X (NPV = +$85,000) and Project Y (NPV = −$12,000) at its 12% cost of capital. Under the NPV rule, the correct decision is to:
Read DetailsCase Scenario C — TechPulse Data-Privacy DilemmaTechPulse In…
Case Scenario C — TechPulse Data-Privacy DilemmaTechPulse Inc. is a mid-sized software company that recently discovered its flagship analytics platform inadvertently collects sensitive personal health information from users who did not consent to that collection. Legal counsel confirms the practice is prohibited in some states but not others, with federal legislation pending. The marketing team views the data as commercially valuable and proposes selling it to pharmaceutical partners for targeted advertising. The CEO is under investor pressure to raise quarterly revenue. Several employees have raised ethical concerns internally and been told to ‘focus on the bottom line,’ and a whistleblower has signaled she may contact regulators if the company proceeds.From a Kantian (deontological) perspective, collecting and monetizing user health data without consent is unethical primarily because it:
Read Details